PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Gazyva

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. Is the prescribing physician a hematologist or oncologist?

☐ Yes ☐ No

Q2. For what diagnosis is the drug being prescribed (pick one)?

☐ Chronic lymphocytic leukemia (CLL), previously untreated
☐ Follicular lymphoma (FL)
☐ Other

Q3. Please provide ICD code(s) for diagnosis

Q4. Please indicate location of administration.

☐ Home
☐ Long Term Care (LTC) facility
☐ Physician office (drug from office stock - buy and bill)
☐ Physician office (drug from pharmacy with a prescription)

Q5. If using for CLL, is member using Gazyva as first-line therapy?

☐ Yes ☐ No

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Gazyva

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**

Q6. If using for CLL, will Gazyva be used in combination with chlorambucil?

☐ Yes ☐ No

Q7. If using for FL, did the patient relapse after or is the patient refractory to a rituximab-containing regimen?

☐ Yes ☐ No

Q8. If using for FL, will Gazyva be used in combination with bendamustine followed by Gazyva monotherapy?

☐ Yes ☐ No

Q9. Additional comments

Prescriber Signature _____ Date _____

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical director at 1-888-316-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.